锌指蛋白 A20 对兔腰椎间盘退变影响的实验研究

目的探讨锌指蛋白 A20 [f9;兔腰椎•f4;盘退变的f71;响。方法取 3 月 f84;新ࢗf;兰大白兔 26 只�ff0c;f53;质जf; 2.0�ff5e;2.5 kg�ff0c;߬f;腹细针ާf;刺法制备 L_3、4、L_4、5、L_5、6 椎•f4;盘退变模型�ff0c;其中 24 只ٲf;后 4 周 MRI 检查明确造模成ԩf;�ff0c;२f;机分为 4 组�ff08;n=6�ff09;�ff0c;于目标椎•f4;盘中分别注射锌指蛋白 A20 fc7;表fbe;腺病毒�ff08;fc7;表fbe; A20 组�ff09;、空f7d;f53;腺病毒�ff08;空f7d;f53;组�ff09;、PBS 液�ff08;[f9;照组�ff09;、锌指蛋白 A20干扰腺病毒�ff08;干扰 A20 组�ff09;。于注射前 1 d 及注射后 1、2、3、6 d 行ݑf;物反应~fc;合评分�ff1b;注射后 2、4、8 周�ff0c;各组行 MRI 检查并测जf; T2 f1b;豫ef6;•f4;�ff08;T2 fe1;Sf7;值�ff09;后�ff0c;取材行ॣf;利f9b;蓝染色观ֽf;椎•f4;盘髓核细胞退变情况�ff0c;免疫组织化学染色检测锌指蛋白 A20 以及椎•f4;盘退变vf8;关指标�ff08;Ⅱ型€f6;Թf;、蛋白聚糖�ff09;的表fbe;�ff0c;Western blot 检测锌指蛋白 A20、NF-κB 结合蛋白�ff3b;P65、xf7;酸化 P65�ff08;phosphate P65�ff0c;P-P65�ff09;、Ⅱ型€f6;Թf;、蛋白聚糖�ff3d;、自噬vf8;关蛋白�ff3b;LC3 �ff08;LC3Ⅱ/LC3Ⅰ�ff09;、P62�ff3d;以及炎症因子�ff08;TNF-α、IL-1β�ff09;的表fbe;。 结果各组注射后各ef6;•f4;点ݑf;物反应~fc;合评分均明显f4e;于注射前 1 d�ff08;P<0.05�ff09;�ff1b;注射后 6 d 干扰 A20 组评分明显f4e;于其他组�ff08;P<0.05�ff09;�ff0c;其他组•f4;比f83;差f02;均无߭f;计学ؐf;义�ff08;P>0.05�ff09;。MRI 检测提示�ff0c;注射后 2、4、8 周fc7;表fbe; A20 组 T2 fe1;Sf7;值均最高�ff08;P<0.05�ff09;�ff0c;2、4 周ef6;干扰 A20 组最f4e;�ff08;P<0.05�ff09;�ff0c;其f59;组•f4;差f02;均无߭f;计学ؐf;义�ff08;P>0.05�ff09;。ॣf;利f9b;蓝染色显示�ff0c;注射后 4 周fc7;表fbe; A20 组蛋白聚糖含जf;最高�ff08;P<0.05�ff09;、干扰 A20 组最f4e;�ff08;P<0.05�ff09;�ff1b;8 周ef6;fc7;表fbe; A20 组蛋白聚糖含जf;显著高于其他组�ff08;P<0.05�ff09;�ff0c;其他组•f4;比f83;差f02;无߭f;计学ؐf;义�ff08;P>0.05�ff09;。免疫组织化学染色示�ff0c;锌指蛋白 A20、Ⅱ型€f6;Թf;、蛋白聚糖表fbe;fc7;表fbe; A20 组最高�ff08;P<0.05�ff09;�ff0c;干扰 A20 组上ff0;蛋白表fbe;最f4e;�ff08;P<0.05�ff09;。Western blot 检测示锌指蛋白 A20、蛋白聚糖、Ⅱ型€f6;Թf;、LC3 �ff08;LC3Ⅱ/LC3Ⅰ�ff09;蛋白vf8;[f9;表fbe;जf;fc7;表fbe; A20 组最高、干扰 A20 组最f4e;�ff0c;而 P-P65、TNF-α、IL-1β、P62 蛋白vf8;[f9;表fbe;जf;fc7;表fbe; A20 组最f4e;、干扰 A20 组最高�ff0c;与其他组比f83;差f02;均有߭f;计学ؐf;义�ff08;P<0.05�ff09;�ff1b;各组 P65 蛋白vf8;[f9;表fbe;जf;差f02;均无߭f;计学ؐf;义�ff08;P>0.05�ff09;。 结论锌指蛋白 A20 €fd;通fc7;抑制炎症反应�ff0c;有效^f6;f13;兔腰椎•f4;盘退变的fdb;程。     

股骨远端去旋转截骨联合内侧髌股韧带重建术治疗复发性髌骨脱位的早期疗效

目的探讨股骨fdc;ޮf;去旋f6c;截骨�ff08;derotational distal femoral osteotomy�ff0c;DDFO�ff09;联合内fa7;髌股韧带�ff08;medial patellofemoral ligament�ff0c;MPFL�ff09;重^fa;ٲf;治疗股骨前倾角�ff08;femoral anteversion angle�ff0c;FAA�ff09;fc7;大�ff08;≥30°�ff09;的复发性髌骨脱f4d;的早ٱf;疗效。方法2017 年 6 月—2019 年 8 月�ff0c;收治 17 f8b; FAA≥30° 的复发性髌骨脱f4d;患者�ff0c;均行 DDFO 联合 MPFL 重^fa;ٲf;治疗。男 5 f8b;�ff0c;女 12 f8b;�ff0c;年 f84; 14�ff5e;22 岁�ff0c;平均 17.7 岁。髌骨脱f4d; 2�ff5e;8 次�ff0c;平均 3.6 次。病程 2�ff5e;7 年�ff0c;平均 4.6 年。膝关节恐惧试验均为阳性。ٲf;前疼痛视觉模حf;评分�ff08;VAS�ff09;以及 Lysholm 评分、Tegner 评分、Kujala 评分分别为�ff08;4.2±1.1�ff09;、�ff08;47.8±8.1�ff09;、�ff08;3.6±1.1�ff09;、�ff08;56.8±5.7�ff09;分�ff0c;f71;Ԍf;学测जf; FAA、股骨fdc;ޮf;外fa7;机械角�ff08;mechanical lateral distal femoral angle�ff0c;mLDFA�ff09;、外fa7;髌骨yfb;f4d;值�ff08;lateral patella displacement�ff0c;LPD�ff09;、胫骨结节-股骨滑f66;•f4;距�ff08;tibial tuberosity-trochlear groove distance�ff0c;TT-TG�ff09;分别为�ff08;34.9±3.4�ff09;°、�ff08;85.8±3.0�ff09;°、�ff08;13.7±3.8�ff09;mm、�ff08;23.1±2.1�ff09;mm。结果患者切口均Ⅰٱf;愈合�ff0c;无膝关节Pf5;硬、ؑf;染及髌骨再次脱f4d;等并发症发ݑf;。患者均获२f;ࢻf;�ff0c;२f;ࢻf;ef6;•f4; 13�ff5e;25 个月�ff0c;平均 17.7 个月。f71;Ԍf;学复查显示�ff0c;1 f8b;截骨不愈合�ff0c;߬f;二次手ٲf;ffb;fee;加f3a;Vfa;定后愈合�ff1b;其f59;患者截骨均于ٲf;后 3�ff5e;4 个月完全愈合。末次२f;ࢻf;ef6;�ff0c;膝关节恐惧试验均为阴性�ff1b;FAA、mLDFA、LPD 以及 TT-TG 分别为�ff08;15.6±2.7�ff09;°、�ff08;83.0±2.1�ff09;°、�ff08;5.0±2.6�ff09;mm、�ff08;20.5±2.5�ff09;mm�ff0c;VAS 评分、Lysholm 评分、Tegner 评分以及 Kujala 评分分别为�ff08;2.4±1.4�ff09;、�ff08;93.4±7.8�ff09;、�ff08;6.8±1.5�ff09;、�ff08;89.0±8.0�ff09;分�ff0c;上ff0;指标与ٲf;前比f83;差f02;均有߭f;计学ؐf;义�ff08;P<0.05�ff09;。 结论DDFO 联合 MPFL 重^fa;ٲf;治疗 FAA fc7;大�ff08;≥30°�ff09;的复发性髌骨脱f4d;Ծf;获f97;ࠦf;好早ٱf;疗效�ff0c;膝关节疼痛明显Ԝf;f7b;、ԩf;€fd;明显改善。     

改性壳聚糖基导电复合材料神经导管的体内降解及组织相容性观察

目的探讨改性Xf3;聚糖Wfa;[fc;电复合材料神߬f;[fc;管的f53;内降解及组织vf8;容性�ff0c;以ٱf;为组织工程神߬f;构^fa;提f9b;新的ْf;架材料。方法采用fae;乳液聚合法合成纳米聚吡Պf;�ff08;polypyrrole�ff0c;PPy�ff09;�ff0c;与Xf3;聚糖共mf7;后注入定制的成管模型�ff0c;冷冻干燥及脱酸后�ff0c;制成改性纳米 PPy/Xf3;聚糖复合材料[fc;管�ff08;记f5c; CP [fc;管�ff09;�ff1b;再߬f;不同程度乙酰化�ff08;乙酰化反应ef6;•f4;分别为 30、60、90 min�ff09;改性�ff0c;制备不同乙酰度的 CP [fc;管�ff08;记f5c; CAP1、CAP2、CAP3 [fc;管�ff09;。各[fc;管予红外光谱、扫ؼf;电镜fdb;行表f81;�ff0c;f7f;用四探针电[fc;仪测定电[fc;率。取 30 只雌性 SD 大 f20;�ff0c;于背部左、Sf3;fa7;各制备 4 个皮下筋膜隧道�ff0c;分别植入上ff0;[fc;管。ٲf;后 2、4、6、8、10、12 周取材�ff0c;大f53;观ֽf;[fc;管f62;态及完整性、扫ؼf;电镜观ֽf;[fc;管fae;观结构、测जf;[fc;管降解率�ff0c;以观ֽf;[fc;管f53;内降解性€fd;�ff1b;行 HE 染色及抗巨噬细胞免疫荧光染色�ff0c;观ֽf;[fc;管f53;内组织vf8;容性。结果߬f;表f81;证实乙酰化改性后的各[fc;管 1 562 cm^–1左Sf3;的酰€fa;Ⅱ谱带增f3a;�ff0c;表示Xf3;聚糖乙酰化改性成ԩf;。各[fc;管均具备[fc;电性€fd;�ff0c;组•f4;电[fc;率差f02;无߭f;计学ؐf;义�ff08;P>0.05�ff09;。扫ؼf;电镜观ֽf;示各[fc;管表面vf8;[f9;光滑、结构f4;密�ff0c;无明显差f02;。[fc;管植入f53;内后�ff0c;२f;ef6;•f4;^f6;ॗf;均Qfa;现一定程度塌陷�ff0c;其中 CAP3 [fc;管尤为明显�ff1b;亦Qfa;现不同程度质जf;丢失�ff0c;且乙酰化度越高�ff0c;质जf;变化越大�ff08;P<0.05�ff09;。扫ؼf;电镜观ֽf;示植入 12 周后材料Qfa;现f83;多孔隙�ff0c;且२f;着乙酰化度增加�ff0c;孔隙呈增大趋ԫf;。组织学观ֽf;显示ٲf;后早ٱf;各[fc;管均有f83;多巨噬细胞、淋]f4;细胞浸润�ff0c;२f;着植入ef6;•f4;^f6;ॗf;�ff0c;淋]f4;细胞有所Ԝf;少、成纤~f4;细胞增多、€f6;Թf;纤~f4;增ݑf;明显。 结论不同乙酰度的改性Xf3;聚糖Wfa;[fc;电复合材料神߬f;[fc;管均有f83;好的f53;内ݑf;物vf8;容性、Ծf;[fc;电、Ծf;降解�ff0c;且降解性与乙酰度vf8;关�ff0c;有望为组织工程神߬f;构^fa;提f9b;一种新的ْf;架材料。     

计算流体力学在组织工程中的应用进展

目的~fc;ff0;计算流f53;力学�ff08;computational fluid dynamics�ff0c;CFD�ff09;在组织工程中的应用fdb;展。方法קf;泛查阅 CFD 应用于组织工程的vf8;关文献�ff0c;主要[f9; CFD 用于ݑf;物反应器设计改ࠦf;或f18;化、模حf;f53;外组织再ݑf;fc7;程中的流f53;动力学和细胞ݑf;ॗf;动力学等方面fdb;行~fc;ff0;。结果CFD 的模حf;预测€fd;力Ծf;为ݑf;物反应器的设计f18;化和f53;外组织工程组织Wf9;养提f9b;重要的指[fc;f5c;用�ff0c;且结合实验研究€fd;fdb;一步提高模型预测结果的准确性。结论CFD f5c;为新兴和有效的研究工具�ff0c;]f2;在组织工程中展现Qfa;独特f18;ԫf;并取f97;显著fdb;展�ff0c;f46;ff4;全面、准确地模حf;组织再ݑf;全fc7;程仍需fdb;一步研究。     

脊柱肿瘤切除术后 3D 打印假体重建的近期疗效

目的总结在脊gf1;ࠋf;瘤切除ٲf;后采用 3D 打印假f53;重^fa;的fd1;ٱf;疗效。方法2019 年 6 月—2020 年6 月�ff0c;[f9; 5 f8b;脊gf1;ࠋf;瘤患者行ࠋf;瘤f7b;底切除后�ff0c;采用 3D 打印假f53;植入f85;助内Vfa;定重^fa;脊gf1;稳定性。男 4 f8b;�ff0c;女 1 f8b;�ff1b;年 f84; 27�ff5e;71 岁�ff0c;平均 50.4 岁。病程 3�ff5e;24 个月�ff0c;平均 9.5 个月。Թf;发ࠋf;瘤 3 f8b;�ff0c;f6c;yfb;瘤 2 f8b;。ࠋf;瘤fb5;ܪf; C₅ 1 f8b;、T₆ 2 f8b;、T₁₂ 1 f8b;、L₂ 1 f8b;。ٲf;前 Frankel 分级均为 E 级�ff0c;疼痛视觉模حf;评分�ff08;VAS�ff09;为�ff08;5.0±2.0�ff09;分�ff0c;Karnofsky ԩf;€fd;状态评分为�ff08;64.0±15.2�ff09;分。ٲf;后给予[f9;应放化疗、fc0;素等f85;助治疗。 结果手ٲf;ef6;•f4;为 180�ff5e;525 min�ff0c;平均 348 min�ff1b;ٲf;中Qfa;血जf; 200�ff5e;2 800 mL�ff0c;平均 1 380 mL。切口均Ⅰٱf;愈合。患者均获२f;ࢻf;�ff0c;२f;ࢻf;ef6;•f4; 5�ff5e;14 个月�ff0c;平均 10.6 个月。ٲf;后除 1 f8b;Qfa;现Sf3;fa7; C₅ 神߬f;根麻uf9;外�ff0c;其f59;患者均无并发症发ݑf;。末次२f;ࢻf;ef6;�ff0c;VAS 评分为�ff08;0.8±0.8�ff09;分�ff0c;Karnofsky ԩf;€fd;状态评分为�ff08;86.0±15.2�ff09;分�ff0c;与ٲf;前比f83;差f02;均有߭f;计学ؐf;义�ff08;P<0.05�ff09;�ff1b;神߬f;ԩf;€fd;无明显变化�ff1b;f71;Ԍf;学复查示患者均无局部复发�ff0c;内Vfa;定物及假f53;f4d;f6e;ࠦf;好�ff0c;假f53;与骨界面融合。 结论脊gf1;ࠋf;瘤切除ٲf;后采用 3D 打印假f53;重^fa;脊gf1;稳定性安全Ծf;行�ff0c;Ծf;获f97;f83;好fd1;ٱf;疗效。     

Binding of antidepressants to human brain receptors: focus on newer generation compounds

Using radioligand binding assays and postmortem normal human brain tissue, we obtained equilibrium dissociation constants (K_ds) for 17 antidepressants and two of their metabolites at histamine H₁, muscarinic, f7j17071l5231125/xxlarge945.gif" alt="agr" align="BASELINE" BORDER="0">₁-adrenergic, f7j17071l5231125/xxlarge945.gif" alt="agr" align="BASELINE" BORDER="0">₂-adrenergic, dopamine D₂, serotonin 5-HT_1A, and serotonin 5-HT₂ receptors. Several newer antidepressants were compared with older drugs. In addition, we studied some antimuscarinic, antiparkinson, antihistamine, and neuroleptic compounds at some of these receptors. For the antidepressants, classical tricyclic antidepressants were the most potent drugs at five of the seven receptors (all but f7j17071l5231125/xxlarge945.gif" alt="agr" align="BASELINE" BORDER="0">₂-adrenergic and 5-HT_1A receptors). The chlorophenylpiperazine derivative antidepressants (etoperidone, nefazodone, trazodone) were the most potent antidepressants at f7j17071l5231125/xxlarge945.gif" alt="agr" align="BASELINE" BORDER="0">₂-adrenergic and 5-HT_1A receptors. Of ten antihistamines tested, none was more potent than doxepin at histamine H₁ receptors. At muscarinic receptors antidepressants and antihistamines had a range of potencies, which were mostly weaker than those for antimuscarinics. From the in vitro data, we expect adinazolam, bupropion, fluoxetine, sertraline, tomoxetine, and venlafaxine not to block any of these five receptors in vivo. An antidepressant's potency for blocking a specific receptor is predictive of certain side effects and drug-drug interactions. These studies can provide guidelines for the clinician in the choice of antidepressant.     

Creative versus repetitive dance therapies to reduce the impact of fibromyalgia and pain: A systematic review and meta-analysis

Background and purposePhysical exercise is one of the most effective interventions to reduce fibromyalgia symptoms. Previous studies have reported benefits of dance-based intervention on the fibromyalgia impact, health-related quality of life and pain, regardless the interventions were based on creative- or repetitive dance. This study aimed to compare the effectiveness of creative and repetitive dance interventions.MethodsPRISMA guidelines were followed in this systematic review. The Cochrane Library, PubMed, Trip, Google Scholar, Web of Science (WOS), Embase and Scopus databases were selected to identify potential articles. Studies were included if they met the following inclusion criteria: to be a clinical trial or a randomized controlled trial, include people with fibromyalgia, have a comparison group and evaluate the impact of the disease, pain or quality of life. Fifteen articles fulfilled the inclusion criteria. The methodological quality of the studies was assessed using the Cochrane Collaboration's tool.ResultsDance-based interventions significantly reduced fibromyalgia impact (standardized mean difference = −0.69), pain (standardized mean difference = −0.70 and increased quality of life (standardized mean difference = 0.43) of people with fibromyalgia. The effectiveness of dance interventions is increased when a creative component is added, since it can lead to higher improvements in pain, impact of the disease and improving quality of life.ConclusionDance-based interventions are significantly effective in reducing the impact of fibromyalgia, pain as well as increasing health-related quality of life. Subgroup analyses suggest that creative dance-based interventions could be more effective than repetitive dance-based interventions to reduce pain and fibromyalgia impact. However, results must be taken with caution due to the large heterogeneity and the small number of articles.     

Decreased phospholipase A2 activity in the brain and in platelets of patients with Alzheimer's disease

Phospholipase A₂ (PLA₂) is a key enzyme in the metabolism of membrane phospholipids. PLA₂ influences the processing and secretion of the amyloid precursor protein, which give rise to the f01578313026t875/xxlarge946.gif" alt="beta" align="MIDDLE" BORDER="0">-amyloid peptide, the major component of the amyloid plaque in Alzheimer's disease (AD). We investigated the PLA₂ activity in two samples: in post-mortem brains from 23 patients with AD and 20 non-demented elderly controls, and platelets from 16 patients with a diagnosis of probable AD, 13 healthy controls and 14 elderly patients with a major depression. In AD brains PLA₂ activity was significantly decreased in the parietal, and to a lesser degree in the frontal, cortex. Lower PLA₂ activity correlated significantly with an earlier onset of the disease, an earlier age at death and higher counts of neurofibrillary tangles and senile plaques. In platelets PLA₂ activity was also significantly reduced in the AD group as compared with healthy and depressed controls. The reduction of the enzyme activity in platelets correlated with an early disease onset and with the severity of cognitive impairment, indicating a relationship between abnormally low PLA₂ activity and a more severe form of the illness. The present results provide new evidence for a disordered phospholipid metabolism in AD brains and suggest that reduced PLA₂ activity may contribute to the production of amyloidogenic peptides in the disease. Further studies are needed to examine whether PLA₂ activity in platelets may be useful as a peripheral marker for a subgroup of patients with AD.